Share
361 Posts.
lightbulb Created with Sketch. 100
clock Created with Sketch. 24/11/20
11:42
Share
Originally posted by Luvit123:
↑
Im no bio expert but to reduce my feeling of 'gambling' I have tried to understand what this business (and sienna is/were) about. I can see that they have been executing on their business plans and BD1 is likely to continue to (as i have faith in the integrity of the board and what they share via announcements makes sense to me, and i can track their milestones against what they said they were up to). I had both BD1 and Sienna (and Race Oncology also) - i wouldn't be surprised if Subb2m gets used in Race breast treatment activities to monitor cancer growth in the future (just seems like the stars are aligning).
Expand
Again good post and agree with your sentiments. For me the most difficult aspect of Biotechs is that the majority remain speculative and end up busting not booming. Its a gamble to get in , things happen slowly and the occasionally..BANG...things change for the better re SP. I have previously stated that I worked with a Doc who badgered me to invest in pnv in 2007 and 2008, finally in 2009 I took a big plunge against the wishes of my wife, accountant and it remained slow for years before reaching every we are now. BD1 has some similarities in that the product is there and the management is there, we have to wait and be patient and it still may not go but the opportunity is there for the SP/Product to be attractive to large institutional investors and other shareholders, please forgive me for being repetitive but mid to late 2021 the position of the company and SP will be when I make a decision about further investment or selling off, DYOR and take care
(20min delay)